• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在小鼠中进行治疗性幽门螺杆菌免疫后,黏膜免疫反应与胃内细菌定植的减少有关。

Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice.

作者信息

Nyström Johanna, Raghavan S, Svennerholm A-M

机构信息

Department of Medical Microbiology and Immunology, Göteborg University Vaccine Research Institute, Göteborg University, Box 435, 405 30 Göteborg, Sweden.

出版信息

Microbes Infect. 2006 Feb;8(2):442-9. doi: 10.1016/j.micinf.2005.07.010. Epub 2005 Sep 22.

DOI:10.1016/j.micinf.2005.07.010
PMID:16243563
Abstract

The aim of this study was to investigate the capacity of oral and parenteral therapeutic immunization to reduce the bacterial colonization in the stomach after experimental Helicobacter pylori infection, and to evaluate whether any specific immune responses are related to such reduction. C57BL/6 mice were infected with H. pylori and thereafter immunized with H. pylori lysate either orally together with cholera toxin or intraperitoneally (i.p.) together with alum using immunization protocols that previously have provided prophylactic protection. The effect of the immunizations on H. pylori infection was determined by quantitative culture of H. pylori from the mouse stomach. Mucosal and systemic antibody responses were analyzed by ELISA in saponin extracted gastric tissue and serum, respectively, and mucosal CD4+ T cell responses by an antigen specific proliferation assay. Supernatants from the proliferating CD4+ T cells were analyzed for Th1 and Th2 cytokines. The oral, but not the parenteral therapeutic immunization induced significant decrease in H. pylori colonization compared to control infected mice. The oral immunization resulted in markedly elevated levels of serum IgG+M as well as gastric IgA antibodies against H. pylori antigen and also increased H. pylori specific mucosal CD4+ T cell proliferation with a Th1 cytokine profile. Although the parenteral immunization induced dramatic increases in H. pylori specific serum antibody titers, no increases in mucosal antibody or cellular immune responses were observed after the i.p. immunization compared to control infected mice. These findings suggest that H. pylori specific mucosal immune responses with a Th1 profile may provide therapeutic protection against H. pylori.

摘要

本研究的目的是调查口服和肠胃外治疗性免疫在实验性幽门螺杆菌感染后减少胃部细菌定植的能力,并评估是否有任何特异性免疫反应与这种减少相关。将C57BL/6小鼠感染幽门螺杆菌,然后使用先前已提供预防性保护的免疫方案,用幽门螺杆菌裂解物与霍乱毒素一起口服或与明矾一起腹腔内(i.p.)免疫。通过对小鼠胃部幽门螺杆菌进行定量培养来确定免疫对幽门螺杆菌感染的影响。分别通过ELISA分析皂苷提取的胃组织和血清中的粘膜和全身抗体反应,并通过抗原特异性增殖试验分析粘膜CD4+T细胞反应。分析增殖的CD4+T细胞的上清液中的Th1和Th2细胞因子。与对照感染小鼠相比,口服而非肠胃外治疗性免疫导致幽门螺杆菌定植显著减少。口服免疫导致血清IgG+M以及针对幽门螺杆菌抗原的胃IgA抗体水平显著升高,并且还增加了具有Th1细胞因子谱的幽门螺杆菌特异性粘膜CD4+T细胞增殖。尽管肠胃外免疫导致幽门螺杆菌特异性血清抗体滴度急剧增加,但与对照感染小鼠相比,腹腔内免疫后未观察到粘膜抗体或细胞免疫反应增加。这些发现表明,具有Th1谱的幽门螺杆菌特异性粘膜免疫反应可能提供针对幽门螺杆菌的治疗性保护。

相似文献

1
Mucosal immune responses are related to reduction of bacterial colonization in the stomach after therapeutic Helicobacter pylori immunization in mice.在小鼠中进行治疗性幽门螺杆菌免疫后,黏膜免疫反应与胃内细菌定植的减少有关。
Microbes Infect. 2006 Feb;8(2):442-9. doi: 10.1016/j.micinf.2005.07.010. Epub 2005 Sep 22.
2
Oral immunization with HpaA affords therapeutic protective immunity against H. pylori that is reflected by specific mucosal immune responses.用HpaA进行口服免疫可提供针对幽门螺杆菌的治疗性保护性免疫,这通过特异性黏膜免疫反应得以体现。
Vaccine. 2007 Mar 30;25(14):2591-8. doi: 10.1016/j.vaccine.2006.12.026. Epub 2006 Dec 26.
3
Mucosal immunization with a urease B DNA vaccine induces innate and cellular immune responses against Helicobacter pylori.用尿素酶B DNA疫苗进行黏膜免疫可诱导针对幽门螺杆菌的固有免疫和细胞免疫反应。
Helicobacter. 2006 Apr;11(2):113-22. doi: 10.1111/j.1523-5378.2006.00385.x.
4
Oral Immunization with a Multivalent Epitope-Based Vaccine, Based on NAP, Urease, HSP60, and HpaA, Provides Therapeutic Effect on Infection in Mongolian gerbils.基于NAP、脲酶、HSP60和HpaA的多价表位疫苗经口免疫对蒙古沙鼠感染具有治疗作用。
Front Cell Infect Microbiol. 2017 Aug 4;7:349. doi: 10.3389/fcimb.2017.00349. eCollection 2017.
5
Mucosal vaccination increases local chemokine production attracting immune cells to the stomach mucosa of Helicobacter pylori infected mice.黏膜疫苗接种会增加局部趋化因子的产生,吸引免疫细胞进入幽门螺杆菌感染小鼠的胃黏膜。
Vaccine. 2012 Feb 21;30(9):1636-43. doi: 10.1016/j.vaccine.2011.12.111. Epub 2012 Jan 9.
6
Oral vaccination against Helicobacter pylori with recombinant cholera toxin B-subunit.用重组霍乱毒素B亚单位进行幽门螺杆菌口服疫苗接种。
Helicobacter. 2005 Aug;10(4):345-52. doi: 10.1111/j.1523-5378.2005.00328.x.
7
Oral immunization with Helicobacter pylori-loaded poly(D, L-lactide-co-glycolide) nanoparticles.用负载幽门螺杆菌的聚(D,L-丙交酯-共-乙交酯)纳米颗粒进行口服免疫。
Helicobacter. 1999 Mar;4(1):33-9. doi: 10.1046/j.1523-5378.1999.09046.x.
8
The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.无毒CTA1-DD佐剂可增强黏膜免疫后针对幽门螺杆菌感染的保护性免疫。
Scand J Immunol. 2006 Feb;63(2):97-105. doi: 10.1111/j.1365-3083.2005.01713.x.
9
Immunogenicity characterization of the multi-epitope vaccine CTB-UE with chitosan-CpG as combination adjuvants against Helicobacter pylori.以壳聚糖-甲基化CpG为联合佐剂的多表位疫苗CTB-UE针对幽门螺杆菌的免疫原性特征分析
Biochem Biophys Res Commun. 2015 Jul 3;462(3):269-74. doi: 10.1016/j.bbrc.2015.04.130. Epub 2015 May 6.
10
Immunological features and efficacy of a multi-epitope vaccine CTB-UE against H. pylori in BALB/c mice model.多表位疫苗CTB-UE在BALB/c小鼠模型中抗幽门螺杆菌的免疫学特征及疗效
Appl Microbiol Biotechnol. 2014 Apr;98(8):3495-507. doi: 10.1007/s00253-013-5408-6. Epub 2013 Dec 28.

引用本文的文献

1
Chitosan Nanoparticles for Enhanced Immune Response and Delivery of Multi-Epitope Vaccines in a BALB/c Mouse Model.壳聚糖纳米颗粒增强BALB/c小鼠模型的免疫反应及多表位疫苗递送
Pharmaceutics. 2025 Jan 18;17(1):132. doi: 10.3390/pharmaceutics17010132.
2
Adjuvants for vaccines: Outer membrane vesicles provide an alternative strategy.疫苗佐剂:外膜囊泡提供了一种替代策略。
Virulence. 2024 Dec;15(1):2425773. doi: 10.1080/21505594.2024.2425773. Epub 2024 Nov 20.
3
Oral Live-Carrier Vaccine of Recombinant Lactococcus lactis Inducing Prophylactic Protective Immunity Against Helicobacter pylori Infection.
重组乳酸乳球菌口服活载体疫苗诱导针对幽门螺杆菌感染的预防性保护免疫
Probiotics Antimicrob Proteins. 2024 Sep 10. doi: 10.1007/s12602-024-10360-x.
4
Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer.细菌裂解物免疫疗法在传染病和癌症中的研究进展。
J Immunol Res. 2024 Jun 12;2024:4312908. doi: 10.1155/2024/4312908. eCollection 2024.
5
An M cell-targeting recombinant L. lactis vaccine against four H. pylori adhesins.一种针对四种 H. pylori 黏附素的 M 细胞靶向重组乳杆菌疫苗。
Appl Microbiol Biotechnol. 2024 Feb 23;108(1):231. doi: 10.1007/s00253-024-13070-0.
6
Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems.颊黏膜和舌下疫苗:口腔黏膜免疫与递送系统综述
Vaccines (Basel). 2021 Oct 14;9(10):1177. doi: 10.3390/vaccines9101177.
7
Outer Membrane Vesicles of 7.13 as Adjuvants Promote Protective Efficacy Against Infection.7.13的外膜囊泡作为佐剂可提高抗感染的保护效力。
Front Microbiol. 2020 Jun 23;11:1340. doi: 10.3389/fmicb.2020.01340. eCollection 2020.
8
Synthetic Lipopeptide Enhances Protective Immunity Against Infection.合成脂肽增强抗感染的保护性免疫。
Front Immunol. 2019 Jun 14;10:1372. doi: 10.3389/fimmu.2019.01372. eCollection 2019.
9
Association between Helicobacter pylori and intestinal parasites in an Añu indigenous community of Venezuela.委内瑞拉阿努土著社区中幽门螺杆菌与肠道寄生虫之间的关联。
Indian J Gastroenterol. 2016 Mar;35(2):106-12. doi: 10.1007/s12664-016-0641-4. Epub 2016 May 2.
10
Defining the Roles of IFN-γ and IL-17A in Inflammation and Protection against Helicobacter pylori Infection.确定IFN-γ和IL-17A在幽门螺杆菌感染的炎症反应及免疫保护中的作用
PLoS One. 2015 Jul 13;10(7):e0131444. doi: 10.1371/journal.pone.0131444. eCollection 2015.